CRNX - CIK 0001658247
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $7.70M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $7.70M | +640.7% |
| FY 2024 | $1.04M | -74.1% |
| FY 2023 | $4.01M | - |
| FY 2022 | $0.00 | - |
| FY 2021 | $0.00 | -100.0% |
| FY 2020 | $71.00K | -94.0% |
| FY 2019 | $1.19M | -50.9% |
| FY 2018 | $2.43M | +18.7% |
| FY 2017 | $2.04M |
Crinetics Pharmaceuticals, Inc. (CRNX) reported revenue of $7.70M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Crinetics Pharmaceuticals, Inc.'s revenue grew from $589.00K to $7.70M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| +247.2% |
| FY 2016 | $589.00K | - |